FDA Panel Gives Nod to Circadian Rhythm Disorder Drug

Published November 23, 2013

FDA Panel Gives Nod to Circadian Rhythm Disorder Drug
[rewrite]In RESET, the percentage of patients with maintenance of entrainment was significantly higher in the treatment group (90%) than in the placebo group (20.0%) About 90% of people in the RESET trial became unentrained once they were taken off the drug …[/rewrite]
Read more on Medscape